Angela D. Pardee, Ph.D.
Affiliations: | 2010 | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
Immunology, OncologyGoogle:
"Angela Pardee"Parents
Sign in to add mentor| Walter J. Storkus | grad student | 2010 | University of Pittsburgh | |
| (Cancer immunotherapy targeting T cell costimulatory molecules.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Vujanovic L, Stahl EC, Pardee AD, et al. (2017) Tumor-derived α-fetoprotein directly drives human natural killer cell activation and subsequent cell death. Cancer Immunology Research |
| Pardee AD, Yano H, Weinstein AM, et al. (2015) Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma. Journal For Immunotherapy of Cancer. 3: 32 |
| Vujanovic L, Stahl E, Pardee A, et al. (2015) Tumor-derived alpha fetoprotein directly impacts human natural killer cell activity and viability Journal For Immunotherapy of Cancer. 3 |
| Santos PM, Pardee A, Delgoffe GM, et al. (2015) Tumor-derived alpha-fetoprotein (tAFP) causes immune and metabolic dysfunction in monocyte-derived dendritic cells Journal For Immunotherapy of Cancer. 3 |
| Pardee AD, Shi J, Butterfield LH. (2014) Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 193: 5723-32 |
| Pardee AD, Shi J, Butterfield LH. (2014) Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells Journal For Immunotherapy of Cancer. 2: 229 |
| Blalock LT, Landsberg J, Messmer M, et al. (2012) Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology. 1: 287-357 |
| Pardee AD, Butterfield LH. (2012) Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology. 1: 48-55 |
| Pardee AD, McCurry D, Alber S, et al. (2010) A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Research. 70: 9041-52 |
| Qu Y, Chen L, Pardee AD, et al. (2010) Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. Journal of Immunology (Baltimore, Md. : 1950). 185: 2895-902 |